Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Navepegritide · Yuviwel, ACP-015

Peptide · Agonist of natriuretic peptide receptor-B (NPR2) · developed by Ascendis

Approved FDA, Feb 2026

ASND Developer

2 Registered trials

What is Navepegritide?

Navepegritide (ACP-015) is a C-type natriuretic peptide (CNP) analog that releases CNP, which binds NPR-B to raise cGMP and signal through protein kinase G, inhibiting MAPK signaling. It is studied in achondroplasia, where it counteracts overactive FGFR3 signaling and promotes chondrocyte growth.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Yuviwel, ACP-015
Drug type: Peptide
Targets: natriuretic peptide receptor-B (NPR2)
Mechanism: Agonist of natriuretic peptide receptor-B (NPR2)
Pathways: cGMP/protein kinase G signaling, MAPK signaling inhibition, endochondral ossification / chondrocyte proliferation and differentiation
Therapy area: Musculoskeletal
Developer: Ascendis (ASND)
FDA status: Approved as Yuviwel (February 27, 2026), NDA219164 · FDA label
UNII: Y3BH8M899D

✅ FDA-approved uses

Achondroplasia

From the indications section of the FDA label (version of Mar 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05598320	Phase 2/3	Achondroplasia	Completed	ASND
NCT06079398	Phase 2	Achondroplasia	Recruiting	ASND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Achondroplasia

Other drugs acting on NPR2

TransCon CNP FDA approved Cenderitide Phase 2

More from Ascendis

Lonapegsomatropin FDA approved Palopegteriparatide FDA approved TransCon CNP FDA approved ACP-001 Phase 2 Resiquimod Hydrogel-based Phase 1/2 TransCon hGH Phase 3 TransCon Treprostinil Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ASND page.

Follow ASND, the company behind Navepegritide

See ASND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASND catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z